MiMedx Net Profit Margin 2010-2025 | MDXG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

MiMedx net profit margin from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

MiMedx net profit margin from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$249.5B
Amgen (AMGN)	$159.2B
Gilead Sciences (GILD)	$144.1B
Vertex Pharmaceuticals (VRTX)	$101.9B
Bristol Myers Squibb (BMY)	$98.6B
GSK (GSK)	$81.7B
CSL (CSLLY)	$69.9B
Regeneron Pharmaceuticals (REGN)	$63.4B
Alnylam Pharmaceuticals (ALNY)	$61.3B
Argenex SE (ARGX)	$40.6B
Insmed (INSM)	$28B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$21.2B
Biogen (BIIB)	$20.4B
Incyte (INCY)	$16.9B
Genmab (GNMSF)	$16.1B
Genmab (GMAB)	$15.7B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Moderna (MRNA)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.5B
Halozyme Therapeutics (HALO)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8B